CHMP recommends EU approval for Roche´s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer
(WorldNews Switzerland)

Basel, 21 July 2017 CHMP recommends EU approval for Roche`s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with metastatic urothelial carcinoma (mUC) who have been previously treated with a platinum based chemotherapy and for people who are ineligible to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for...